British Technology Group Limited

Societe D'etudes Scientifiques Et Industrielles De L'ile-de-france

National Research Development Corporation

E. R. Squibb Sons, Inc.

Laboratoires Delagrange (synthelabo)

Laboratoires Delagrange Div. Societe D'applications Pharmacodynamiques

Laboratoires Delagrange Societe D'application Pharmacodynamiques

Laboratoires Delagrange Societe D'applications Pharmacodnymiques

Societe D'etudes Scientifiques Et Industrielle De L'ile-d-france

Brenda Costall

Robert J Naylor

Jacques Acher

Jean-Claude Monier

Jean-Paul Schmitt

Renee Gardaix-Luthereau

Edward A Boyd

Mary E Kelly

Philip J Parsons

Zola P Horovitz

Denis Besancon

Peter Jenner

Gardaix-Luthereau Renee

Charles D Marsden

Benzo�d! isoxazole derivatives, compositions containing them and their

Compounds of formula (I) ##STR1## in which R.sub.1 represents hydrogen, a C.sub.1-6 aliphatic hydrocarbyl group or a C.sub.1-4 aliphatic hydrocarbyl group substituted by a C.sub.3-6 alicyclic hydrocarbyl group or by a phenyl group, which phenyl group is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, R.sub.2 represents hydrogen, R.sub.3 represents hydrogen, a 5-or 6-membered ring aromatic heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen and sulphur which is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, or a group AR wherein A is a straight chain C.sub.1-4 aliphatic hydrocarbyl group terminally substituted by R which is hydrogen, a phenyl group or a 5-or 6-membered ring aromatic heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen and sulphur, which phenyl or heterocyclyl group R is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, R.sub.4 and R.sub.5 each represent hydrogen or together represent an oxo group and R.sub.6, R.sub.7 and R.sub.8 each represent hydrogen, or R.sub.4 represents hydrogen and two of R.sub.5, R.sub.6, R.sub.7 and R.sub.8 together represent the second bond of a double bond joining positions 4 and 5, 5 and 6 or 6 and 7 with the remaining two of R.sub.5, R.sub.6, R.sub.7 and R.sub.8 representing hydrogen, the compound optionally being in the form of a salt thereof formed with a physiologically acceptable inorganic or organic acid, are of value for the treatment of anxiety and in the improvement of learning ability and/or the reversal of amnesia.

Pharmaceutical compositions

Compounds of formula (I) ##STR1## in which R.sub.1 represents hydrogen, a C.sub.1-6 aliphatic hydrocarbyl group or a C.sub.1-4 aliphatic hydrocarbyl group substituted by a C.sub.3-6 alicyclic hydrocarbyl group or by a phenyl group, which phenyl group is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, R.sub.2 represents hydrogen, R.sub.3 represents hydrogen, a 5- or 6-membered ring aromatic heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen and sulphur which is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, or a group AR wherein A is a straight chain C.sub.1-4 aliphatic hydrocarbyl group terminally substituted by R which is hydrogen, a phenyl group or a 5- or 6-membered ring aromatic heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen and sulphur, which phenyl or heterocyclyl group R is unsubstituted or substituted by a halogeno or C.sub.1-3 halogenoalkyl group, R.sub.4 and R.sub.5 each represent hydrogen or together represent an oxo group and R.sub.6, R.sub.7 and R.sub.8 each represent hydrogen, or R.sub.4 represents hydrogen and two of R.sub.5, R.sub.6, R.sub.7 and R.sub.8 together represent the second bond of a double bond joining positions 4 and 5, 5 and 6 or 6 and 7 with the remaining two of R.sub.5, R.sub.6, R.sub.7 and R.sub.8 representing hydrogen, the compound optionally being in the form of a salt thereof formed with a physiologically acceptable inorganic or organic acid, are of value for the treatment of anxiety and in the improvement of learning and/or the reversal of amnesia.

Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines of the Formula I ##STR1## wherein: R.sub.1 represents hydrogen or C.sub.1 -C.sub.4 alkyl;

Memory-enhancing compositions containing dioxopiperidine derivatives

Anxiolytic and antipsychotic treatment is provided to patients by administering therapeutically effective amounts of N-[2-(diethylamino)-ethyl]-2-methoxy-4-[(1-H-4,5-dihydro-2-imidazolyl)-ami no]-5-chlorobenzamide, or a pharmaceutically acceptable salt thereof.

Method of providing anxiolytic and antipsychotic treatment

The present invention relates to the use of substituted benzamides of formula (1): ##STR1## in which: A is linear or branched C.sub.1 -C.sub.3 alkyl; allyl or diethylaminoethyl;

Method of increasing gastrointestinal motility with substituted

Anxiolytic and antipsychotic treatment is provided to patients by administering therapeutically effective amounts of N-[2-(diethylamino)-ethyl]-2-methoxy-4-[(1-H-4,5-dihydro-2-immidazolyl)-am ino]-5-chlorobenzamide, or a pharmaceutically acceptable salt thereof.

The invention relates to the use of benzamide derivatives of the formula: ##STR1## in which: A is a diethylaminoethyl group or a group of the formula II: ##STR2## where R is a C.sub.1 -C.sub.3 alkyl, allyl, cyclopropylmethyl or cyclohexenylmethyl group,

Method of treating disorders of cognitive function with substituted

A method is provided for imhibiting loss of cognitive functon, including memory, which may or may not be associated with Alzheimer's disease, by administering an ACE inhibitor, such as captopril, fosinopril, zofenopril or ceranapril in combination with a drug that acts as serotonin receptors such as zacopride, over a prolonged period of treatment.

Method for preventing or inhibiting loss of cognitive function employing

The present invention relates to the application of substituted benzamides of formula (I): ##STR1## in which: A is diethylaminoethyl, 1-ethyl-2-pyrrolidinylmethyl or 1-allyl-2-pyrrolidinylmethyl;

Method of providing anxiolytic and antipsychotic treatment with

New substituted benzamides have the general formula: ##STR1## their optical isomers and their physiologically acceptable salts. The compounds are used as activators of the central nervous system.

Novel benzamides, intermediates and process for the preparation and

Antipsychotic compositions containing dioxopiperidine derivatives

New substituted benzamides have the general formula: ##STR1## A=alkyl, alkenyl, diethylaminoethyl or ##STR2## R.sub.1, R.sub.2 =H, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl; R.sub.3, R.sub.4, R.sub.5, R.sub.6 =hydrogen or C.sub.1 -C.sub.6 alkyl;

The use of N-(1-allyl-2-pyrrolidinylmethyl) 2-methoxy 4-amino 5-methylsulphamoyl benzamide to treat Parkinson's disease.

Growing community of inventors

Addingham, United Kingdom

Brenda Costall